 Atara Biotherapeutics, Inc. Nasdaq: ATRA, a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop treatments for patients with severe diseases, including solid tumors, hematologic cancers and autoimmune disease, today announced the Company will release second quarter 2020 financial results after market close on Wednesday, August 5, 2020. Following the release, the Company will host a live conference call and webcast at 4:30 p.m. EDT to discuss the Companys financial results and provide a corporate update. 